Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Sold by Acuta Capital Partners LLC

Acuta Capital Partners LLC decreased its stake in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBPFree Report) by 71.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,500 shares of the biopharmaceutical company’s stock after selling 46,000 shares during the quarter. Acuta Capital Partners LLC owned approximately 0.15% of Corbus Pharmaceuticals worth $382,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of CRBP. MetLife Investment Management LLC purchased a new stake in shares of Corbus Pharmaceuticals during the third quarter worth approximately $123,000. SG Americas Securities LLC acquired a new position in Corbus Pharmaceuticals during the 3rd quarter worth approximately $151,000. FMR LLC increased its position in shares of Corbus Pharmaceuticals by 33.0% in the 3rd quarter. FMR LLC now owns 10,028 shares of the biopharmaceutical company’s stock valued at $207,000 after purchasing an additional 2,486 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Corbus Pharmaceuticals by 7.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 22,731 shares of the biopharmaceutical company’s stock valued at $469,000 after purchasing an additional 1,600 shares in the last quarter. Finally, Victory Capital Management Inc. raised its holdings in shares of Corbus Pharmaceuticals by 29.9% in the 3rd quarter. Victory Capital Management Inc. now owns 24,760 shares of the biopharmaceutical company’s stock valued at $511,000 after purchasing an additional 5,700 shares in the last quarter. Institutional investors and hedge funds own 64.64% of the company’s stock.

Insider Activity at Corbus Pharmaceuticals

In related news, major shareholder Cormorant Asset Management, Lp purchased 350,000 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The shares were purchased at an average price of $20.01 per share, for a total transaction of $7,003,500.00. Following the transaction, the insider now directly owns 2,375,000 shares of the company’s stock, valued at approximately $47,523,750. The trade was a 17.28 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.00% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Oppenheimer increased their target price on Corbus Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a report on Wednesday, August 7th. Mizuho reissued an “outperform” rating and set a $74.00 target price on shares of Corbus Pharmaceuticals in a research report on Friday, September 20th. B. Riley decreased their target price on Corbus Pharmaceuticals from $85.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, September 20th. Royal Bank of Canada reiterated an “outperform” rating and issued a $82.00 price target on shares of Corbus Pharmaceuticals in a research note on Friday, September 20th. Finally, Lifesci Capital upgraded shares of Corbus Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Corbus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $65.86.

View Our Latest Analysis on CRBP

Corbus Pharmaceuticals Trading Down 1.9 %

CRBP stock opened at $17.64 on Thursday. The company has a market capitalization of $214.86 million, a P/E ratio of -3.76 and a beta of 2.56. The business has a 50 day simple moving average of $18.91 and a 200-day simple moving average of $39.99. Corbus Pharmaceuticals Holdings, Inc. has a twelve month low of $4.06 and a twelve month high of $61.90.

Corbus Pharmaceuticals Profile

(Free Report)

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.

Featured Articles

Institutional Ownership by Quarter for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.